AMGEN FILES 8-K ON FINANCIAL RESULTS, EXHIBITS

TL;DR

**Amgen just dropped its latest financial results, so expect market reaction.**

AI Summary

Amgen Inc. filed an 8-K on February 6, 2024, to report its results of operations and financial condition, along with related financial statements and exhibits. This filing, under SEC File Number 001-37702, indicates that the company is providing updated financial information, likely its full-year 2023 earnings. This matters to investors because it provides crucial insights into Amgen's financial health and performance, which can directly influence stock price and future investment decisions.

Why It Matters

This filing provides investors with the latest financial performance data for Amgen, which is essential for evaluating the company's health and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results, which is standard for public companies and does not inherently carry high risk.

Analyst Insight

A smart investor would review the full financial statements and results once they become available to understand Amgen's performance and future outlook before making any investment decisions.

Key Numbers

• 001-37702 — Commission File Number (identifies Amgen's registration with the SEC)
• 95-3540776 — IRS Employer Identification No. (Amgen's tax identification number)
• (805) 447-1000 — Business Phone (Amgen's primary contact number)

Key Players & Entities

• Amgen Inc. (company) — the registrant filing the 8-K
• February 6, 2024 (date) — date of earliest event reported and filing date
• 001-37702 (dollar_amount) — Amgen's Commission File Number
• The Nasdaq Stock Market LLC (company) — exchange where Amgen's common stock and senior notes are registered

FAQ

From the Filing

0000318154-24-000004.txt : 20240206 0000318154-24-000004.hdr.sgml : 20240206 20240206162007 ACCESSION NUMBER: 0000318154-24-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240206 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240206 DATE AS OF CHANGE: 20240206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 24600523 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 8-K 1 amgn-202312318xk.htm 8-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024  - Amgen Inc. (Exact name of registrant as specified in its charter)    Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Amgen Center Drive   Thousand Oaks California 91320-1799 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (805) 447-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value AMGN The Nasdaq Stock Market LLC 2.000% Senior Notes due 2026 AMGN26 The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. Fourth Quarter 2023 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On February 6, 2024, the Company issued a press release announcing its unaudited results of operations for the three months and year ended December 31, 2023, and its unaudited financial position as of December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission. The non-GAAP financial measures included in the press release are non-GAAP earnings per share, non-GAAP operating income, non-GAAP o